newsonline24

Charta der Vielfalt – under the patronage of German Chancellor Olaf Scholz – aims to promote diversity in companies and institutions. The initiative has the objective of advancing the recognition, appreciation and inclusion of diversity in the workplace in Germany. In signing the charter, Fresenius Medical Care commits to creating a work environment where all employees are valued – regardless of age, ethnic origin and nationality, gender and gender identity, physical and mental abilities, religion and ideology, sexual orientation and social background.

Helen Giza, CEO of Fresenius Medical Care, said: “Fresenius Medical Care’s commitment towards diversity, equity and inclusion is key to unlocking greater innovation and creating long-term value for our patients and the communities we serve. Signing the Charta der Vielfalt is a testament to our dedication to cultivating a sense of belonging in an environment where every employee feels safe, welcome, and appreciated.”

In 2022, the Company issued three global policies, focusing on promoting diversity, equity, and inclusion, supporting employee groups, and diversity in recruitment.

To date, the Company has 16 employee groups supporting Women Leaders, the LatinX1 community and more, enabling employees to come together for professional and personal development, and peer support. Fresenius Medical Care also educates its leaders on how to model inclusive behaviors. Furthermore, to promote gender diversity, the company has set itself the goal of increasing the overall representation of women in management positions to reflect the percentage of women in the global employee population by 2030.

More information on Fresenius Medical Care’s commitment can be found in the Company’s Non-Financial Group Report 2022.

Disclaimer:

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, impacts related to COVID-19, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forwardlooking statements in this release.